J&J will put an end to Alcon

Discussion in 'Alcon' started by anonymous, Sep 16, 2016 at 6:33 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    With the acquisition of AMO by J&J the days of Alcon's domination of the cataract market is over. Novartis did the the prep work and J&J will finish it off.
     

  2. anonymous

    anonymous Guest

    Novartis already got the part of Alcon they wanted. Surgical is sold within a year.
     
  3. anonymous

    anonymous Guest

    first of J&J shows they not as stupid as NVS and buy a decent ophthalmic company at a decent price.

    Secondly J&J knows how to run device company and will not bull shit around like the joker win Alcon leadership.

    Ball,
    this is the last warning get rid of the fucking morons you have in the name of leaders in Asia if you want us to survive.
     
  4. anonymous

    anonymous Guest

    Nobody wants to buy Alcon anymore…
     
  5. anonymous

    anonymous Guest

    This is going to be a war now.
    J&J doesn't need to do anything to beat Alcon as NVS is already screwing it.

    All they need to do is get the surgical talent fired in recent years by nvs back. Not only will they readily join there are plenty more currently in Alcon who will jump at this opportunity.
    And all of them will come back with vengeance at NVS.

    Also see Alcon not safe haven anymore
    http://mobile.reuters.com/article/idUSKCN11L1QX
     
  6. anonymous

    anonymous Guest

    how much did Nvs paid for ALCON? How many much did JNJ pay for amo ??
     
  7. anonymous

    anonymous Guest

    The next step for J&J will be to buy an eye care business, which means either Alcon or B&L.
     
  8. anonymous

    anonymous Guest

    J&J Rocks.......
     
  9. anonymous

    anonymous Guest

    J&J to Buy Abbott’s Eye-Surgery Equipment Unit for $4.325 billion

    Novartis bought into Alcon in three main stages, first purchasing $10.4 billion worth of Alcon shares from Nestlé for $143 a piece in 2008; then buying out the rest of the food company’s interest for $28.1 billion this year, at $180 a share. Altogether, the cost for Novartis comes to $51.6 billion, including a cash supplement of up to $900 million.
     
  10. anonymous

    anonymous Guest

    ???
     
  11. anonymous

    anonymous Guest

    No, they have contact lens already and just got surgical equipment and solutions. They can easily buy generic drugs/drops to bundle where helpful to them for surgery. Next step is to drive Alcon into the ground by becoming a leaner, better run version of what Alcon could have been and taking up share rapidly. They have the company systems, organization, and marketing experience. Party's over in Fort Worth.
     
  12. anonymous

    anonymous Guest

    I will be happy to attend Alcon's funeral and then Novartis's too, later.
    They are both horrible companies, with bad "leaders". Novartis will break up alcon and sell its parts, soon. Novartis will be exposed later with all these bad decisions that have made, including all the offshoring, NBS etc....
    One thing is certain JJ doesn't care what the employees think.
     
  13. anonymous

    anonymous Guest

    throughout all this, who made and will make money? consultants and financiers.
     
  14. anonymous

    anonymous Guest

    It would take a long time. Alcon is the leader in the surgical market and it takes years to convert competitor accounts.
     
  15. anonymous

    anonymous Guest

    So you say...
     
  16. anonymous

    anonymous Guest

    You obviously are not familiar with the surgical division. Must mean you are from Novartis.
     
  17. anonymous

    anonymous Guest

    J&J surgical...And you from knowitall...
     
  18. anonymous

    anonymous Guest

    And why would you be on an Alcon message board?
     
  19. anonymous

    anonymous Guest

    There's a J&J surgical? What do they make?